This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hideshima T et al. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7: 585–598
Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063–3067
Weber DM et al. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357: 2133–2142
Palumbo A et al. (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22: 414–423
Rajkumar SV et al. (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 110: 74a
Palumbo A et al. (2007) Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol 25: 4459–4465
Acknowledgements
The synopsis was written by Mandy Aujla, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P Richardson is on the speaker's bureau of Celgene and Millenium. K Anderson and N Munshi are Consultants, on the speaker's bureau and receive grant/research support from Celgene and Millenium. C Mitsiades declared no competing interests.
Rights and permissions
About this article
Cite this article
Munshi, N., Mitsiades, C., Richardson, P. et al. Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Rev Clin Oncol 5, 374–375 (2008). https://doi.org/10.1038/ncponc1151
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncponc1151
This article is cited by
-
Erratum: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
Nature Clinical Practice Oncology (2008)